MX387359B - Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos. - Google Patents
Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos.Info
- Publication number
- MX387359B MX387359B MX2019010642A MX2019010642A MX387359B MX 387359 B MX387359 B MX 387359B MX 2019010642 A MX2019010642 A MX 2019010642A MX 2019010642 A MX2019010642 A MX 2019010642A MX 387359 B MX387359 B MX 387359B
- Authority
- MX
- Mexico
- Prior art keywords
- intermediaries
- mitogen
- inhibitors
- synthesis
- activated kinase
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 229940124789 MK2 inhibitor Drugs 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472024P | 2017-03-16 | 2017-03-16 | |
| PCT/US2018/022547 WO2018170203A1 (en) | 2017-03-16 | 2018-03-15 | Mk2 inhibitors, synthesis thereof, and intermediates thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019010642A MX2019010642A (es) | 2019-10-17 |
| MX387359B true MX387359B (es) | 2025-03-18 |
Family
ID=63523971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019010642A MX387359B (es) | 2017-03-16 | 2018-03-15 | Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10894796B2 (https=) |
| EP (1) | EP3596086A4 (https=) |
| JP (1) | JP7282039B2 (https=) |
| CN (1) | CN110678471B (https=) |
| AU (1) | AU2018236290B2 (https=) |
| CA (1) | CA3054826A1 (https=) |
| MX (1) | MX387359B (https=) |
| WO (1) | WO2018170203A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62017B1 (sr) | 2014-09-17 | 2021-07-30 | Celgene Car Llc | Mk2 inhibitori i njihova upotreba |
| US11098057B2 (en) * | 2017-03-16 | 2021-08-24 | Celgene Car Llc | 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof |
| EP3596085A4 (en) | 2017-03-16 | 2020-11-25 | Celgene CAR LLC | DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES |
| WO2018170200A1 (en) * | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Heteroaryl compounds useful as mk2 inhibitors |
| WO2018170203A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Mk2 inhibitors, synthesis thereof, and intermediates thereto |
| US10882867B2 (en) | 2017-03-16 | 2021-01-05 | Celgene Car Llc | Forms and compositions of a MK2 inhibitor |
| WO2020236636A1 (en) * | 2019-05-17 | 2020-11-26 | Celgene Car Llc | Methods of treating a mk2-mediated disorder |
| CN116670142A (zh) * | 2021-02-01 | 2023-08-29 | 细胞基因公司 | Mk2抑制剂、其合成和其中间体 |
| WO2023025298A1 (zh) * | 2021-08-27 | 2023-03-02 | 瑞石生物医药有限公司 | 喹啉并呋喃衍生物及其用途 |
| EP4464694A4 (en) | 2022-01-14 | 2026-04-01 | Shanghai Hansoh Biomedical Co Ltd | POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE |
| CN116643046B (zh) * | 2023-05-30 | 2025-09-12 | 南昌市高新区人民医院(南昌大学第一附属医院高新医院) | Mk2在癌症恶病质肌肉萎缩中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200504898B (en) | 2002-12-20 | 2006-11-29 | Pharmacia Corp | Acyclic pyrazole compounds |
| US20060106020A1 (en) | 2004-04-28 | 2006-05-18 | Rodgers James D | Tetracyclic inhibitors of Janus kinases |
| EP2223925A1 (en) | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| MX2009014247A (es) | 2007-07-16 | 2010-01-28 | Novartis Ag | Compuestos heterociclicos utiles como inhibidores de mk2. |
| KR101598397B1 (ko) | 2008-04-22 | 2016-02-29 | 얀센 파마슈티카 엔.브이. | 퀴놀린 또는 이소퀴놀린 치환된 피2엑스7 안타고니스트 |
| WO2011062765A2 (en) | 2009-11-17 | 2011-05-26 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| EP2588455B1 (en) | 2010-07-02 | 2018-04-04 | Gilead Sciences, Inc. | 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds |
| ES2546465T3 (es) | 2010-10-29 | 2015-09-23 | Pfizer Inc | Inhibidores de N1/N2-lactama acetil-CoA carboxilasa |
| EP2635284B1 (en) * | 2010-11-01 | 2019-12-18 | Celgene CAR LLC | Heterocyclic compounds and uses thereof |
| SI2648516T1 (sl) * | 2010-12-06 | 2019-01-31 | Aclaris Therapeutics, Inc. | Substituirane spojine piridinon-piridinila |
| JP6189434B2 (ja) | 2012-07-10 | 2017-08-30 | アレス トレーディング ソシエテ アノニム | ピリミジンピラゾリル誘導体 |
| WO2014011902A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CA2908098A1 (en) | 2013-03-15 | 2014-09-25 | Celgene Avilomics Research, Inc. | Mk2 inhibitors and uses thereof |
| CN104177340A (zh) * | 2013-05-22 | 2014-12-03 | 中国中化股份有限公司 | 一种新型的喹唑啉（硫）酮类化合物及其用途 |
| WO2015128884A1 (en) | 2014-02-27 | 2015-09-03 | Council Of Scientific & Industrial Research | Poly-benzimidazole with pyrene and anthracene flourophore |
| EP3179858B1 (en) * | 2014-08-13 | 2019-05-15 | Celgene Car Llc | Forms and compositions of an erk inhibitor |
| RS62017B1 (sr) | 2014-09-17 | 2021-07-30 | Celgene Car Llc | Mk2 inhibitori i njihova upotreba |
| US10407422B2 (en) | 2015-09-03 | 2019-09-10 | Bristol-Myers Squibb Company | Triazolopyridine inhibitors of myeloperoxidase |
| WO2018170203A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Mk2 inhibitors, synthesis thereof, and intermediates thereto |
| WO2018170200A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Heteroaryl compounds useful as mk2 inhibitors |
| US10882867B2 (en) | 2017-03-16 | 2021-01-05 | Celgene Car Llc | Forms and compositions of a MK2 inhibitor |
| US11098057B2 (en) | 2017-03-16 | 2021-08-24 | Celgene Car Llc | 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof |
| EP3596085A4 (en) | 2017-03-16 | 2020-11-25 | Celgene CAR LLC | DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES |
| WO2020236636A1 (en) | 2019-05-17 | 2020-11-26 | Celgene Car Llc | Methods of treating a mk2-mediated disorder |
| KR20230044446A (ko) | 2020-07-24 | 2023-04-04 | 브리스톨-마이어스 스큅 컴퍼니 | 급성 호흡기 장애의 치료 방법 |
| CN116670142A (zh) | 2021-02-01 | 2023-08-29 | 细胞基因公司 | Mk2抑制剂、其合成和其中间体 |
-
2018
- 2018-03-15 WO PCT/US2018/022547 patent/WO2018170203A1/en not_active Ceased
- 2018-03-15 EP EP18768733.0A patent/EP3596086A4/en not_active Withdrawn
- 2018-03-15 CA CA3054826A patent/CA3054826A1/en active Pending
- 2018-03-15 AU AU2018236290A patent/AU2018236290B2/en not_active Ceased
- 2018-03-15 MX MX2019010642A patent/MX387359B/es unknown
- 2018-03-15 CN CN201880032092.8A patent/CN110678471B/zh not_active Expired - Fee Related
- 2018-03-15 JP JP2019550605A patent/JP7282039B2/ja active Active
- 2018-03-15 US US16/494,701 patent/US10894796B2/en active Active
-
2021
- 2021-01-14 US US17/148,903 patent/US11655257B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11655257B2 (en) | 2023-05-23 |
| US20200102326A1 (en) | 2020-04-02 |
| WO2018170203A1 (en) | 2018-09-20 |
| EP3596086A1 (en) | 2020-01-22 |
| CN110678471A (zh) | 2020-01-10 |
| JP7282039B2 (ja) | 2023-05-26 |
| CA3054826A1 (en) | 2018-09-20 |
| US20210139501A1 (en) | 2021-05-13 |
| CN110678471B (zh) | 2022-09-13 |
| EP3596086A4 (en) | 2020-12-16 |
| AU2018236290B2 (en) | 2022-06-02 |
| JP2020510063A (ja) | 2020-04-02 |
| MX2019010642A (es) | 2019-10-17 |
| AU2018236290A1 (en) | 2019-09-19 |
| US10894796B2 (en) | 2021-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX387359B (es) | Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos. | |
| CY1120988T1 (el) | Παρεμποδιστες διαρυλ κινασης | |
| CL2022000448A1 (es) | Autoinyector (divisional solicitud no. 201903061) | |
| IL282468A (en) | 2- amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
| PH12018501151A1 (en) | Tank-binding kinase inhibitor compounds | |
| CY1124097T1 (el) | Κρυσταλλικο πολυμορφο της ελευθερης βασης της 2-υδροξυ-6-((2-(1-ισοπροπυλο-1η-πυραζολ-5-υλο)πυριδιν-3-υλο)μεθοξυ)βενζαλδεϋδης | |
| MX373341B (es) | INHIBIDORES DE PROTEíNA CINASA 2 ACTIVADA POR PROTEíNA CINASA ACTIVADA POR MITóGENO (MK2) Y SUS USOS. | |
| MA51616A (fr) | Inhibiteurs d'adn-pk | |
| MX2016015862A (es) | Compuestos inhibidores de la cinasa de union a tank. | |
| GEP20217234B (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
| EA201891626A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| AR111304A1 (es) | Métodos para sintetizar un inhibidor de mcl-1 | |
| ECSP16067303A (es) | Heteroarilos y usos de estos | |
| AR095039A1 (es) | Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico | |
| MX2017003930A (es) | Derivados de aminotriazina utiles como compuestos inhibidores de la cinasa de union a tank. | |
| MX393600B (es) | Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2). | |
| EA201992147A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| MX2020013630A (es) | Analogos de rapamicina y usos de los mismos. | |
| ZA202002951B (en) | Albumin-binding prodrugs of auristatin e derivatives | |
| MY188420A (en) | Crystalline forms of (s)-afoxolaner | |
| JOP20210036A1 (ar) | مثبطات او- جليكوبروتين-2-أسيتاميدو-2-ديوكسي-3-دي-جلوكوبيرانوسيداز | |
| HUE062726T2 (hu) | 1-(1,2-dimetilpropil)-N-etil-5-metil-N-piridazin-4-il-pirazol-4-karboxamid kristályos formái | |
| MX374654B (es) | Compuestos útiles para inhibir ror-gamma-t. | |
| CY1123406T1 (el) | Παραγωγο τριαζολοπυραζινονης χρησιμο ως ενας ανθρωπινος pde1 αναστολεας | |
| CL2021000663A1 (es) | Proceso para la producción de gas de síntesis. |